Patients and Healthcare Providers to Experience Significant Benefits from the Use of the Internet

The growth of Internet applications in healthcare has been rapid. A growing number of patients are becoming increasingly involved in the healthcare service they receive. These 'power patients' possess characteristics that distinguish them from traditional patients and are an important factor in driving the use of the Internet in healthcare.

"Power patients are a growing share of the population and healthcare organisations will need to meet their needs," notes Frost & Sullivan (http://healthcareIT.frost.com) Industry Analyst Konstantinos Nikolopoulos. "Free choice of doctors, control over treatments received, access to quality information about their care and extremely high levels of customer service are some of the expectations of power patients."

Besides, over the years, healthcare organisations have had to adapt to numerous changes, from advances in diagnostic and therapeutic procedures to the emergence of concepts such as managed care and telemedicine. The e-Health model represents another such change with far-reaching implications for healthcare organisations. In such a scenario, the Internet's capability to empower patients, support information exchange and thus result in new operational strategies, business and service delivery models can be very appealing although quite challenging.

Moreover, public health policies and regulations greatly influence the way in which healthcare organisations can use the Internet. For instance, uncertainty over privacy and security regulations regarding the use of electronic health information can deter organisations from sharing health records or administrative and financial information across the Internet.

"The transition to electronic healthcare and the use of the Internet to exchange health information raises serious security concerns," explains Nikolopoulos. "While the perception of the lack of security is inhibiting the use of the Internet for sharing clinical information, various technologies and procedures are being developed to deal with these security problems."

The European Union is already enforcing strict medical data security standards and the North American market is also demanding improved security and confidentiality in healthcare transactions with the Health Insurance Portability and Accountability Act (HIPAA).

In this scenario, all stakeholders will need to realise that in matters concerning security, privacy and confidentiality, ensuring 100 per cent absolute security and confidentiality is impossible. Instead, maintaining a good balance between actual or realistic needs, risks, costs and potential losses (including the impact on reputation), is essential. Until there is widespread consensus on such issues, security concerns will continue to inhibit the use of the Internet in healthcare.

The Role of the Internet in Healthcare is part of the Healthcare & Life Sciences IT Growth Partnership Service, which also includes research on patient data safety in the European healthcare IT markets, the computerised physician order entry systems market, the electronic medical records market and the hospital information systems market in Europe. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of the Role of the Internet in Healthcare, send an e-mail to Radhika Menon Theodore, Corporate Communications, at This email address is being protected from spambots. You need JavaScript enabled to view it. with your full name, company name, title, telephone number, e-mail address, city, state and country.

About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

New research paper shows that AstraZeneca has achi…

In a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity f...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Berry gives boost to cervical cancer therapy

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most...

Novartis appoints Elizabeth Barrett as Oncology He…

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the E...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]